feedback

Course Director

Anas Younes, MD
Anas Younes, MD

Memorial Sloan Kettering Cancer Center
New York, New York

Faculty

Robert Chen
Robert Chen, MD

Toni Stephenson Lymphoma Center
City of Hope Medical Center
Duarte, California

Joseph M. Connors
Joseph M. Connors, MD, FRCPC

BC Cancer Centre for Lymphoid Cancer
University of British Columbia
Vancouver, British Columbia, Canada

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:0.5 Credits
Release Date:2018-May-30
Expiration Date:2019-May-29
Registration Required:No
Cost:Free

Activity Description and Educational Objectives

In this activity, experts in Hodgkin lymphoma (HL) discuss new evidence and progress in frontline management, as well as practical issues related to the safe and effective use of antibody–drug conjugates and immunotherapies, including combination regimens, in the HL setting.

Upon completion of this activity, participants should be better able to:

  • Define current and emerging frontline treatment regimens for patients with Hodgkin lymphoma (HL)
  • Select appropriate dosing when integrating novel therapies into the management of newly diagnosed HL
  • Manage treatment-emergent adverse events in patients with HL receiving novel antibody-based and other therapies

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, advanced practice hematology-oncology nurses, and other clinicians involved in the care of patients with Hodgkin lymphoma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: May 30, 2018 - May 29, 2019
Time to Complete: 30 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Anas Younes, MD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Anas Younes, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb Company; Curis, Inc.; F. Hoffmann-La Roche Ltd; Johnson & Johnson Inc.; and Novartis Pharmaceuticals Corporation.
Honoraria from Bayer Corporation; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc./Millennium Pharmaceuticals, Inc.
Anas Younes, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors in the frontline setting and combination regimen of antibody drug conjugate and immune checkpoint inhibitor in different treatment settings for management of Hodgkin lymphoma.

Faculty

Robert Chen, MD
Associate Professor of Medicine
Associate Director of Toni Stephenson Lymphoma Center
City of Hope Medical Center
Duarte, California

Robert Chen, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb Company; Merck & Co., Inc.; and Seattle Genetics, Inc.
Speakers Bureau participant with Merck & Co., Inc. and Seattle Genetics, Inc.
Advisory Board for Bristol-Myers Squibb Company; Merck & Co., Inc.; and Seattle Genetics, Inc.
Robert Chen, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors in the frontline setting and combination regimen of antibody drug conjugate and immune checkpoint inhibitor in different treatment settings for management of Hodgkin lymphoma.

Joseph M. Connors, MD, FRCPC
Clinical Professor of Medicine
Clinical Director, BC Cancer Centre for Lymphoid Cancer
University of British Columbia
Vancouver, British Columbia, Canada

Joseph M. Connors, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Amgen Inc.; Bayer Corporation; Bristol-Myers Squibb Company; Cephalon; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Janssen Inc.; Merck & Co., Inc.; Millennium: The Takeda Oncology Company; NanoString Technologies, Inc.; Roche; and Seattle Genetics, Inc.
Joseph M. Connors, MD, FRCPC, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors in the frontline setting and combination regimen of antibody drug conjugate and immune checkpoint inhibitor in different treatment settings for management of Hodgkin lymphoma.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Seattle Genetics.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.